Plus: BioCryst-Astria rounds out HAE, Praxis’ essential tremor pill succeeds in Phase 3, and Rocket’s LAD-I gene therapy returns to FDA review (Oct 10-16, 2025).
Trump cuts IVF & Medicaid drug prices; Novo…
Plus: BioCryst-Astria rounds out HAE, Praxis’ essential tremor pill succeeds in Phase 3, and Rocket’s LAD-I gene therapy returns to FDA review (Oct 10-16, 2025).